Bio-Techne stock trades at EUR 64.94 in late Wednesday session

Published on 11/05/2026 at 01:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bio-Techne develops reagents, instruments and precision diagnostics for research and clinical testing. Its portfolio supports drug discovery and laboratory work.

Bio-Techne business and market context

Bio-Techne develops reagents, analytical instruments and precision diagnostics for research, drug discovery and clinical testing.
The company is headquartered in Minneapolis, Minnesota, and sells products to researchers and clinicians worldwide.
The latest company results page lists fiscal 2026 adjusted operating margin at 32.2% and adjusted earnings per share at USD 0.52.

Bio-Techne, US09073M1045, Illustration mit AI erstellt.

Bio-Techne stock traded at EUR 64.94 on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4, 2026. The company operates in life sciences, supplying tools used in biological research, drug discovery and clinical diagnostics.

Bio-Techne's investor relations site lists fiscal 2026 adjusted operating margin at 32.2% and adjusted earnings per share at USD 0.52. Its latest quarterly-results section also shows revenue of USD 321.2 million for the reported period. These figures give investors operating and earnings reference points as the company serves research and diagnostic markets.

Products span research and diagnostics

Bio-Techne develops, manufactures and supplies reagents, analytical instruments and precision diagnostics. Its solutions are designed to help researchers generate biological insights, accelerate drug discovery and support accurate clinical testing. The company is incorporated in Minneapolis, Minnesota, and serves customers worldwide.

Investors can follow the real-time quote of Bio-Techne stock.

Broader US equity trading can be followed through the S&P 500 market overview.

More company coverage is available in more news and analyses on Bio-Techne stock.